nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—Feeling abnormal—Teniposide—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Flecainide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Flecainide—Skin discolouration—Methotrexate—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Flecainide—Renal failure—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Flecainide—Nausea—Mechlorethamine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Flecainide—Alopecia—Bleomycin—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Flecainide—Jaundice—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Flecainide—Urticaria—Teniposide—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Flecainide—Abdominal pain—Teniposide—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Flecainide—Body temperature increased—Teniposide—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Flecainide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Flecainide—Hallucination—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Flecainide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Flecainide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Flecainide—Haematuria—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Flecainide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Flecainide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Flecainide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Flecainide—Visual impairment—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Flecainide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Flecainide—Fatigue—Fludarabine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Flecainide—Hallucination—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Flecainide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Flecainide—Pain—Fludarabine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Flecainide—Constipation—Fludarabine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Flecainide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Flecainide—Eye disorder—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Flecainide—Flushing—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Flecainide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Flecainide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Flecainide—Asthenia—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Flecainide—Malaise—Bleomycin—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Flecainide—Pruritus—Teniposide—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Flecainide—Leukopenia—Bleomycin—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Flecainide—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Flecainide—Alopecia—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Flecainide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Flecainide—Cough—Bleomycin—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Flecainide—Diarrhoea—Teniposide—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Flecainide—Chest pain—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Flecainide—Myalgia—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Flecainide—Alopecia—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Flecainide—Coma—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Flecainide—Discomfort—Bleomycin—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Flecainide—Urine output increased—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Flecainide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Flecainide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Flecainide—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Flecainide—Confusional state—Bleomycin—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Flecainide—Vision blurred—Carmustine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Flecainide—Tremor—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Flecainide—Oedema—Bleomycin—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Flecainide—Vomiting—Teniposide—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Flecainide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Flecainide—Asthenia—Fludarabine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Flecainide—Rash—Teniposide—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Flecainide—Dermatitis—Teniposide—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Flecainide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Flecainide—Headache—Teniposide—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Flecainide—Pruritus—Fludarabine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Flecainide—Leukopenia—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Flecainide—Anorexia—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Flecainide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Flecainide—Polyuria—Methotrexate—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Flecainide—Hypotension—Bleomycin—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Flecainide—Diarrhoea—Fludarabine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Flecainide—Convulsion—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Flecainide—Hypertension—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Flecainide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Flecainide—Nausea—Teniposide—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Flecainide—Vertigo—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Flecainide—Hepatic failure—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Flecainide—Leukopenia—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Flecainide—Myalgia—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Flecainide—Chest pain—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Flecainide—Anxiety—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Flecainide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Flecainide—Malaise—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Flecainide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Flecainide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Flecainide—Convulsion—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Flecainide—Hypertension—Vincristine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Flecainide—Confusional state—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Flecainide—Oedema—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Flecainide—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Flecainide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Flecainide—Myalgia—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Flecainide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Flecainide—Cough—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Flecainide—Vomiting—Fludarabine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Flecainide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Flecainide—Rash—Fludarabine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Flecainide—Dermatitis—Fludarabine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Flecainide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Flecainide—Pain—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Flecainide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Flecainide—Headache—Fludarabine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Flecainide—Tachycardia—Carmustine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Flecainide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Flecainide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Flecainide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Flecainide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Flecainide—Discomfort—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Flecainide—Oedema—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Flecainide—Anorexia—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Flecainide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Flecainide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Flecainide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Flecainide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Flecainide—Hypotension—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Flecainide—Oedema—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Flecainide—Nausea—Fludarabine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Flecainide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Flecainide—Shock—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Flecainide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Flecainide—Urticaria—Bleomycin—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Flecainide—Anorexia—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Flecainide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Flecainide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Flecainide—Insomnia—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Flecainide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Flecainide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Flecainide—Paraesthesia—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Flecainide—Hypotension—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Flecainide—Dyspnoea—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Flecainide—Somnolence—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Flecainide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Flecainide—Ataxia—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Flecainide—Decreased appetite—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Flecainide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Flecainide—Insomnia—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Flecainide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Flecainide—Paraesthesia—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Flecainide—Constipation—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Flecainide—Pain—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Flecainide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Flecainide—Decreased appetite—Vincristine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Flecainide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Flecainide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Flecainide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Flecainide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Flecainide—Fatigue—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Flecainide—Asthenia—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Flecainide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Flecainide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Flecainide—Constipation—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Flecainide—Pain—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Flecainide—Pruritus—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Flecainide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Flecainide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Flecainide—Pain—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Flecainide—Constipation—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Flecainide—Abdominal pain—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Flecainide—Body temperature increased—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Flecainide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Flecainide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Flecainide—Dysuria—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Flecainide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Flecainide—Body temperature increased—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Flecainide—Abdominal pain—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Flecainide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Flecainide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Flecainide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Flecainide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Flecainide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Flecainide—Pneumonia—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Flecainide—Vomiting—Bleomycin—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Flecainide—Rash—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Flecainide—Dermatitis—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Flecainide—Asthenia—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Flecainide—Renal failure—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Flecainide—Haematuria—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Flecainide—Asthenia—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Flecainide—Diarrhoea—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Flecainide—Nausea—Bleomycin—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Flecainide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Flecainide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Flecainide—Dizziness—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Flecainide—Diarrhoea—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Flecainide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Flecainide—Vomiting—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Flecainide—Dizziness—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Flecainide—Rash—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Flecainide—Dermatitis—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Flecainide—Visual impairment—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Flecainide—Headache—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Flecainide—Eye disorder—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Flecainide—Tinnitus—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Flecainide—Vomiting—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Flecainide—Rash—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Flecainide—Dermatitis—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Flecainide—Headache—Vincristine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Flecainide—Nausea—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Flecainide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Flecainide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Flecainide—Rash—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Flecainide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Flecainide—Headache—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Flecainide—Alopecia—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Flecainide—Nausea—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Flecainide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000987	0.000987	CcSEcCtD
Flecainide—Nausea—Mitoxantrone—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Flecainide—Vision blurred—Methotrexate—lymphatic system cancer	0.000949	0.000949	CcSEcCtD
Flecainide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Flecainide—Malaise—Methotrexate—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Flecainide—Vertigo—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Flecainide—Leukopenia—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Flecainide—Cough—Methotrexate—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Flecainide—Convulsion—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Flecainide—Myalgia—Methotrexate—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Flecainide—Arthralgia—Methotrexate—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Flecainide—Chest pain—Methotrexate—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Flecainide—Discomfort—Methotrexate—lymphatic system cancer	0.000847	0.000847	CcSEcCtD
Flecainide—Confusional state—Methotrexate—lymphatic system cancer	0.000829	0.000829	CcSEcCtD
Flecainide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000806	0.000806	CcSEcCtD
Flecainide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
Flecainide—Skin disorder—Methotrexate—lymphatic system cancer	0.000799	0.000799	CcSEcCtD
Flecainide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Flecainide—Anorexia—Methotrexate—lymphatic system cancer	0.000784	0.000784	CcSEcCtD
Flecainide—Hypotension—Methotrexate—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
Flecainide—Insomnia—Methotrexate—lymphatic system cancer	0.000744	0.000744	CcSEcCtD
Flecainide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000738	0.000738	CcSEcCtD
Flecainide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000733	0.000733	CcSEcCtD
Flecainide—Somnolence—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Flecainide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000724	0.000724	CcSEcCtD
Flecainide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000715	0.000715	CcSEcCtD
Flecainide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00071	0.00071	CcSEcCtD
Flecainide—Fatigue—Methotrexate—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
Flecainide—Pain—Methotrexate—lymphatic system cancer	0.000703	0.000703	CcSEcCtD
Flecainide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Flecainide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000672	0.000672	CcSEcCtD
Flecainide—Urticaria—Methotrexate—lymphatic system cancer	0.000653	0.000653	CcSEcCtD
Flecainide—Abdominal pain—Methotrexate—lymphatic system cancer	0.00065	0.00065	CcSEcCtD
Flecainide—Body temperature increased—Methotrexate—lymphatic system cancer	0.00065	0.00065	CcSEcCtD
Flecainide—Asthenia—Methotrexate—lymphatic system cancer	0.00059	0.00059	CcSEcCtD
Flecainide—Pruritus—Methotrexate—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Flecainide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000563	0.000563	CcSEcCtD
Flecainide—Dizziness—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Flecainide—Vomiting—Methotrexate—lymphatic system cancer	0.000523	0.000523	CcSEcCtD
Flecainide—Rash—Methotrexate—lymphatic system cancer	0.000518	0.000518	CcSEcCtD
Flecainide—Dermatitis—Methotrexate—lymphatic system cancer	0.000518	0.000518	CcSEcCtD
Flecainide—Headache—Methotrexate—lymphatic system cancer	0.000515	0.000515	CcSEcCtD
Flecainide—Nausea—Methotrexate—lymphatic system cancer	0.000488	0.000488	CcSEcCtD
